SCHEMBL4475372

SCHEMBL4475372

COc1cc2nccc(Oc3ccc(NC(=O)NC4CCCC(C)(C)C4)c(F)c3)c2cc1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.67
PDGFRA P16234 10/20 0.67
AXL P30530 5/20 0.67
KIT P10721 3/20 0.67
FGFR2 P21802 2/20 0.67
MET P08581 4/20 0.60
FGFR4 P22455 2/20 0.58
RIPK2 O43353 1/20 0.54
ERN1 O75460 1/20 0.54
STK10 O94804 1/20 0.54
MAP3K6 O95382 1/20 0.54
ABL1 P00519 1/20 0.54
ESR1 P03372 1/20 0.54
RET P07949 1/20 0.54
PDGFRB P09619 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
BCR P11274 1/20 0.54
FGFR1 P11362 1/20 0.54
NQO2 P16083 1/20 0.54
FLT1 P17948 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13936784 0.94 KDR (0.60) KDRPDGFRAAXLKITFGFR2
SCHEMBL4476901 0.91 FGFR4 (0.67) KDRPDGFRAAXLKITFGFR2
SCHEMBL4487730 0.89 MET (0.58) KDRPDGFRAAXLKITFGFR2
SCHEMBL1892464 0.88 KDR (0.76) KDRPDGFRAAXLKITFGFR2
SCHEMBL4473556 0.88 KDR (0.53) KDRPDGFRAAXLKITFGFR2
SCHEMBL4470899 0.88 PDGFRA (0.79) KDRPDGFRAKITMETAURKB
SCHEMBL4482063 0.87 KDR (0.67) KDRPDGFRAAXLKITFGFR2
SCHEMBL4475674 0.85 PDGFRA (0.62) KDRPDGFRAAXLKITMET
SCHEMBL1897808 0.82 KDR (0.77) KDRPDGFRAAXLKITFGFR2
SCHEMBL1897677 0.82 KDR (0.77) KDRPDGFRAAXLKITFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 KDR 211/4885PDGFRA 372/4885AXL 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.